Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
Status:
Not yet recruiting
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in
preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the
investigators want to find out if they can adjust the dose of alemtuzumab used as part of
allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal
therapeutic window of 0.2-0.6 ug/mL.